Alto Neuroscience, Inc.
$26.41-0.9%YTD+48.5%1Y+564.8%
Price updated 7m ago·X counts updated 2d ago
On X
The complete picture of $ANRO on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.
1X posts · last 7 days
AI verdictAI analysisGenerated by AI from underlying data
TickerTalks' own read on what's driving $ANRO — fundamentals, momentum, or an event — and whether it agrees with the X crowd.
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Biotechnology sits in its cycle right now — and what that implies for $ANRO.
Biotechnology
No material change from last week — mRNA oncology platform remains the structural driver.
What this means for $ANRO
Neutral — Clinical-stage biopharma using AI biomarkers to develop precision psychiatry drugs for treatment-resistant depression and PTSD.
Top industry ETF
$IBBiShares Biotechnology ETF
+24.2%YTD
+48.0%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
-14.7How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
18.4%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
-5.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
-46.5%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q2 2026Aug 12, 2026$-0.65$-0.73+11.5%
Q1 2026May 13, 2026$-0.80$-0.56-42.9%
Q4 2025Mar 16, 2026$-0.45$-0.56+19.6%
Q3 2025Nov 12, 2025$-0.52$-0.66+21.2%
Next earningsWed, Nov 11·consensus EPS $-0.67
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$0———$-0.65$-19.8M
Q1 FY26$0———$-0.80$-27.6M
Q4 FY25$0———$-0.51$-11.5M
Q3 FY25$0———$-0.52$-9.9M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$0$0 – $0-$2.78-$2.96 – -$2.470
FY27$0$0 – $0-$3.07-$3.91 – -$1.920
FY28$6.2M$6.2M – $6.2M-$3.05-$4.39 – -$2.196
FY29$40.6M$40.6M – $40.6M-$3.00-$3.00 – -$3.004
FY30$216.7M$216.7M – $216.7M-$0.65-$0.65 – -$0.653
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.68%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-14.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+13.4%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatLow float · 35.1M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.165-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
SEC filings
Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.
Recent material filings
8-KOfficer or director changeAug 278-K — Item 5.02: Officer or director change
AI summary
8-KMaterial agreementJul 148-K — Item 1.01: Material agreement
AI summary
424B5Prospectus supplement (offering)Jul 14424B5
AI summary
8-KOfficer or director changeMay 288-K — Item 5.02: Officer or director change
8-KOfficer or director changeMay 138-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
+ 17 other (9 13Gs · 2 10-Qs · 2 earnings 8-Ks · 1 8-K) in window
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
Alto Neuroscience Announces Participation in Upcoming Investor ConferencesAlto Neuroscience Announces Participation in Upcoming Investor ConferencesAlto Neuroscience, Inc. (NYSE:ANRO) Receives $37.25 Average PT from AnalystsAlto Neuroscience Promotes Nick Smith to President and Chief Financial OfficerAWM Investment Company Inc. Purchases New Holdings in Alto Neuroscience, Inc. $ANRO
In themes
Explore the broader themes this ticker is being talked about under.
More in Biotechnology
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $ANRO on X in the last 7 days.